Treatment of allergic asthma by targeting transcription factors using nucleic-acid based technologies

Current Pharmaceutical Design

Volumn 12, Issue 25, 2006, Pages 3293-3304

  Sel, Serdar ^a   Henke, Wolfgang ^b   Dietrich, Alexander ^c   Herz, Udo ^a,d   Renz, Harald ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d Mead Johnson Nutritionals GmbH   (Germany)

Author keywords

Allergy; Antisense; Asthma; Nucleic acid based technology; Therapeutic tool; Transcription factor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AUTACOID; CYTOKINE; FOMIVIRSEN; HAMMERHEAD RIBOZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; NUCLEOTIDE DERIVATIVE; OLIGONUCLEOTIDE; ONCOPROTEIN; PLEIOTROPHIN; POLYETHYLENEIMINE; REPRESSOR PROTEIN; RIBOZYME; SMALL INTERFERING RNA; STAT6 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR NFAT;

ALLERGIC ASTHMA; ASTHMA; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG TARGETING; FOOD ALLERGY; GENE TECHNOLOGY; GROWTH INHIBITION; HAY FEVER; HUMAN; MONKEY; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RABBIT; RAT; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; T LYMPHOCYTE; TH2 CELL; THROMBOCYTOPENIA; TUMOR GROWTH;

ALLERGENS; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; GENE TARGETING; GENE THERAPY; HUMANS; NUCLEIC ACIDS; TRANSCRIPTION FACTORS;

EID: 33748575899     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778194150     Document Type: Review

References (153)

1. Lebedeva I, Stein CA. Antisense oligonucleotides: promise and reality. Annu Rev Pharmacol Toxicol 2001; 41: 403-19.
2. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-44.
3. Dove A. Antisense and sensibility. Nat Biotechnol 2002; 20: 121-4.
4. Koller E, Gaarde WA, Monia BP. Elucidating cell signaling mechanisms using antisense technology. Trends Pharmacol Sci 2000; 21: 142-8.
5. Holmlund JT. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development. Ann N Y Acad Sci 2003; 1002: 244-51.
6. Agrawal S, Zhao Q. Antisense therapeutics. Curr Opin Chem Biol 1998, 2: 519-28.
7. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998; 92: 712-36.
8. Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997; 385: 721-5.
9. Sandrasagra A, Leonard SA, Tang L, Teng K, Li Y, Ball HA, et al. Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev 2002; 12: 177-81.
10. Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 2001; 193: 1247-60.
11. Stenton GR, Ulanova M, Dery RE, Merani S, Kim MK, Gilchrist M, et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immmunol 2002; 169: 1028-36.
12. Karras JG, McGraw K, McKay RA, Cooper SR, Lerner D, Lu T, et al. Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma. J Immunol 2000; 164: 5409-15.
13. Fiset PO, Soussi-Gounni A, Christodoulopoulos P, Tulic M, Sobol SE, Frenkiel S, et al. Modulation of allergic response in nasal mucosa by antisense oligodeoxynucleotides for IL-4. J Allergy Clin Immunol 2003; 111: 580-6.
14. Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990; 250: 997-1000.
15. Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000; 106: 1071-5.
16. Crinelli R, Bianchi M, Gentilini L, Magnani M. Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res 2002; 30: 2435-43.
17. Borgatti M, Lampronti I, Romanelli A, Pedone C, Saviano M, Bianchi N, et al. Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem 2003; 278: 7500-9.
18. Romanelli A, Pedone C, Saviano M, Bianchi N, Borgatti M, Mischiati C, et al. Molecular interactions with nuclear factor kappaB (NF-kappaB) transcription factors of a PNA-DNA chimera mimicking NF-kappaB binding sites. Eur J Biochem 2001; 268: 6066-75.
19. Lee IK, Ahn JD, Kim HS, Park JY, Lee KU. Advantages of the circular dumbbell decoy in gene therapy and studies of gene regulation. Curr Drug Targets 2003; 4: 619-23.
20. Cech TR, Zaug AJ, Grabowski PJ. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell 1981; 27: 487-96.
21. Doherty EA, Doudna JA. Ribozyme structures and mechanisms. Anon Rev Biochem 2000; 69: 597-615.
22. DeRose VJ. Two decades of RNA catalysis. Chem Biol 2002; 9: 961-9.
23. Forster AC, Symons RH. Self-cleavage of virusoid RNA is performed by the proposed 55-nucleotide active site. Cell 1987; 50: 9-16.
24. Conaty J, Hendry P, Lockett T. Selected classes of minimised hammerhead ribozyme have very high cleavage rates at low Mg2+ concentration. Nucleic Acids Res 1999; 27: 2400-7.
25. Ryu KJ, Lee SW. identification of the most accessible sites to ribozymes on the hepatitis C virus internal ribosome entry site. J Biochem Mol Biol 2003; 36: 538-44.
26. Scherr M, Rossi JJ. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Res 1998; 26: 5079-85.
27. Scherr M, Rossi JJ, Sczakiel G, Patzel V. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res 2000; 28: 2455-61.
28. Sohail M, Southern EM. Selecting optimal antisense reagents. Adv Drug Deliv Rev 2000; 44: 23-34.
29. Lai J, Gold MS, Kim CS, Bian D, Ossipov MH, Hunter JC, et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain 2002; 95: 143-52.
30. Aigner A, Fischer D, Merdan T, Brus C, Kissel T, Czubayko F. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther 2002; 9: 1700-7.
31. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997; 94: 4262-6.
32. Cairns MJ, King A, Sun LQ. Optimisation of the 10-23 DNAzyme-substrate pairing interactions enhanced RNA cleavage activity at purine-cytosine target sites. Nucleic Acids Res 2003; 31: 2883-9.
33. Cairns MJ, Hopkins TM, Witherington C, Wang L, Sun LQ. Target site selection for an RNA-cleaving catalytic DNA. Nat Biotechnol 1999; 17: 480-6.
34. Dass CR, Saravolac EG, Li Y, Sun LQ. Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev 2002; 12: 289-99.
35. Schubert S, Gul DC, Grunert HP, Zeichhardt H, Erdmann VA, Kurreck J. RNA cleaving '10-23' DNAzymes with enhanced stability and activity. Nucleic Acids Res 2003; 31: 5982-92.
36. Vester B, Lundberg LB, Sorensen MD, Babu BR, Douthwaite S, Wengel J. LNAzymes: incorporation of LNA-type monomers into DNAzymes markedly increases RNA cleavage. J Am Chem Soc 2002; 124: 13682-3.
37. Khan AU, Lal SK. Ribozymes: a modern tool in medicine. J Biomed Sci 2003; 10: 457-67.
38. Lewin AS, Hauswirth WW. Ribozyme gene therapy: applications for molecular medicine. Trends Mol Med 2001; 7: 221-8.
39. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
40. Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci USA 1998; 95: 15502-7.
41. Napoli C, Lemieux C, Jorgensen R. Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. Plant Cell 1990; 2: 279-89.
42. Van der Krol AR, Mur LA, Beld M, Mol JN, Stuitje AR. Flavonoid genes in petunia: addition of a limited number of gene copies may lead to a suppression of gene expression. Plant Cell 1990; 2: 291-9.
43. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21 -nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.
44. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002; 26: 199-213.
45. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003; 4: 457-67.
46. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-3.
47. Cheng JC, Moore TB, Sakamoto KM. RNA interference and human disease., Mol Genet Metab 2003; 80: 121-8.
48. Stevenson M. Dissecting HIV-1 through RNA interference. Nat Rev Immunol 2003; 3: 851-8.
49. Zamore PD. Ancient pathways programmed by small RNAs. Science 2002; 296: 1265-9.
50. Feinberg EH, Hunter CP. Transport of dsRNA into cells by the transmembrane protein SID-1. Science 2003; 301: 1545-7.
51. McManus MT, Haines BB, Dillon CP, Whitehurst CE, van Parijs L, Chen J, et al. Small interfering RNA-mediated gene silencing in T lymphocytes. J Immunol 2002; 169: 5754-60.
52. Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 2003; 33: 396-400.
53. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16: 948-58.
54. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003; 9: 493-501.
55. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-6.
56. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-8.
57. Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA 2003; 100: 1844-8.
58. Kobayashi N, Matsui Y, Kawase A, Hirata K, Miyagishi M, Taira K, et al. Vector-based in vivo RNA interference: dose- and time-dependent suppression of transgene expression. J Pharmacol Exp Ther 2004; 308: 688-93.
59. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834-9.
60. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34: 263-4.
61. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-45.
62. Hartert TV, ebles RS, Jr. Epidemiology of asthma: the year in review. Curr Opin Pulm Med 2000; 6: 4-9.
63. Liew FY. T(H)1 and T(H)2 cells: a historical perspective. Nat Rev Immunol 2002; 2: 55-60.
64. O'Garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation..Trends Cell Biol 2000; 10: 542-50.
65. Rao A, Avni O. Molecular aspects of T-cell differentiation. Br Med Bull 2000; 56: 969-84.
66. Umetsu DT, Akbari O, Dekruyff RH. Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol 2003; 112: 480-7.
67. Renz H, Saloga J, Bradley KL, Loader JE, Greenstein JL, Larsen G, et al. Specific V beta T cell subsets mediate the immediate hypersensitivity response to ragweed allergen. J Immunol 1993; 151: 1907-17.
68. Cohn L, Tepper JS, Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not TH1, cells. J Immunol 1998; 161: 3813-6.
69. Ray A, Cohn L. Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. J Clin Invest 1999; 104: 985-93.
70. Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 2000; 14: 1693-711.
71. Zhang DH, Cohn L, Ray P, Bottomly K, Ray A. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem 1997; 272: 21597-603.
72. Ouyang W, Ranganath SH, Weindel K, Bhattacharya D, Murphy TL, Sha WC, et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998, 9: 745-55.
73. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 587-96.
74. Ranganath S, Ouyang W, Bhattarcharya D, Sha WC, Grupe A, Peltz G, et al. GATA-3-dependent enhancer activity in IL-4 gene regulation. J Immunol 1998; 161: 3822-6.
75. Lee GR, Fields PE, Flavell RA. Regulation of IL-4 gene expression by distal regulatory elements and GATA-3 at the chromatin level. Immunity 2001; 14: 447-59.
76. Lee HJ, Takemoto N, Kurata H, Kamogawa Y, Miyatake S, O'Garra A, et al. GATA-3 induces T helper cell -type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J Exp Med 2000; 192: 105-15.
77. Usui T, Nishikomori R, Kitani A, Strober W. GATA-3 suppresses Th1 development by downregulation of Stat4 and not through effects on IL-12Rbeta2 chain or T-bet. Immunity 2003; 18: 415-28.
78. Ouyang W, Lohning M, Gao Z, Assenmacher M, Ranganath S, Radbruch A, et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 2000; 12: 27-37.
79. Pandolfi PP, Roth ME, Karis A, Leonard MW, Dzierzak E, Grosveld FG, et al. Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nat Genet 1995; 11: 40-4.
80. Ting CN, Olson MC, Barton KP, Leiden JM. Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 1996; 384: 474-8.
81. Nakamura Y, Ghaffar O, Olivenstein R, Taha RA, Soussi-Gounni A, Zhang DH, et al. Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Inummol 1999; 103: 215-22.
82. Zhang DH, Yang L, Cohn L, Parkyn L, Homer R, Ray P, et al. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity 1999; 11: 473-82.
83. Hernandez-Hoyos G, Anderson MK, Wang C, Rothenberg EV, Alberola-Ila J. GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation. Immunity 2003; 19: 83-94.
84. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111: 677-90.
85. Wills-Karp M, Chiaramonte M. Interleukin-13 in asthma. Curr Opin Pulm Med 2003; 9: 21-7.
86. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21: 425-56.
87. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003; 300: 1527-8.
88. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, et al. Lack of EL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380: 630-3.
89. Takeda K, Tanaka T, Shi W,.Matsumoto M, Minami M, Kashiwamura S, et al. Essential role of Stat6 in IL-4 signalling. Nature 1996; 380: 627-30.
90. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4: 313-9.
91. Kuperman D, Schofield B, Wills-Karp M, Grusby MJ. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med 1998; 187: 939-48.
92. Akimoto T, Numata F, Tamura M, Takata Y, Higashida. N, Takashi T, et al. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med 1998; 187: 1537-42.
93. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261-3.
94. Wills-Karp M, Luyimbazi J, Xu X, Schofied B, Neben TY, Karp CL, et al. Interleukin-13: central mediator of allergic asthma. Science 1998, 282: 2258-61.
95. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103: 779-88.
96. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, et al. Direct effects of interleukin-13 on epithelial cells causè airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002; 8: 885-9.
97. Hill S, Herlaar E, Le Cardinal A, van Heeke G, Nicklin P. Homologous human and murine antisense oligonucleotides targeting stat6. Functional effects on germline cepsilon transcript. Am J Respir Cell Mol Biol 1999; 21: 728-37.
98. Wang LH, Yang XY, Kirken RA, Resau JH, Farrar WL. Targeted disruption of stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven T(H)2 cell response. Blood 2000; 95: 1249-57.
99. Stutz AM, Hoeck J, Natt F, Cuenoud B, Woisetschlager M. Inhibition of interleukin-4- and CD40-induced IgE germline gene promoter activity by 2′-aminoethoxy-modified triplex-forming oligonucleotides. J Biol Chem 2001; 276: 11759-65.
100. Hill S, Herlaar E, Le Cardinal A, van Heeke G, Nicklin P. Homologous human and murine antisense oligonucleotides targeting stat6. Functional effects on germline cepsilon transcript. Am J Respir Cell Mol Biol 1999; 21: 728-37.
101. Danahay H, Hill S, Natt F, Owen CE. The in vitro and in vivo pharmacology of antisense oligonucleotides targeted to murine Stat6. Inflamm Res 2000; 49: 692-9.
102. Wang LH, Yang XY, Kirken RA, Resau JH, Farrar WL. Targeted disruption of stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven T(H)2 cell response. Blood 2000; 95: 1249-57.
103. Kraus J, Borner C, Giannini E, Hollt V. The role of nuclear factor kappaB in tumor necrosis factor-regulated transcription of the human mu-opioid receptor gene. Mol Pharmacol 2003; 64: 876-84.
104. Stutz AM, Hoeck J, Natt F, Cuenoud B, Woisetschlager M. Inhibition of interleukin-4- and CD40-induced IgE germline gene promoter activity by 2′-aminoethoxy-modified triplex-forming oligonucleotides. J Biol Chem 2001, 276: 11759-65.
105. Ho IC, Hodge MR, Rooney JW, Glimcher LH. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996; 85: 973-83.
106. Kim JI, Ho IC, Grusby MJ, Glimcher LH. The transcription factor c-Maf controls the production of interleukin-4 but not other Th2 cytokines. Immunity 1999; 10: 745-51.
107. Ho IC, Lo D, Glimcher LH. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J Exp Med 1998; 188: 1859-66.
108. Li-Weber M, Salgame P, Hu C, Davydov IV, Laur O, Klevenz S, et al. Th2-specific protein/DNA interactions at the proximal nuclear factor-AT site contribute to the functional activity of the human IL-4 promoter. J Immunol 1998; 161: 1380-9.
109. Kimura M, Koseki Y, Yamashita M, Watanabe N, Shimizu C, Katsumoto T, et al. Regulation of Th2 cell differentiation by mel-18, a mammalian polycomb group gene. Immunity 2001; 15: 275-87.
110. van Lohuizen M. The trithorax-group and polycomb-group chromatin modifiers: implications for disease. Curr Opin Genet Dev 1999; 9: 355-61.
111. Senftleben U, Karin M. The IKK/NF-kappa B pathway. Crit Care Med 2002; 30: S18-S26.
112. Dunne A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003; 2003: re3.
113. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003; 66: 1403-8.
114. Ruland J, Mak TW. From antigen to activation: specific signal transduction pathways linking antigen receptors to NF-kappaB. Semin Immunol 2003; 15: 177-83.
115. Barnes PJ, Adcock IM. NF-kappa B: a pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci 1997; 18: 46-50.
116. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-42.
117. Wright JG, Christman JW. The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2003; 2: 211-9.
118. Propst SM, Denson R, Rothstein E, Estell K, Schwiebert LM. Proinflammatory and Th2-derived cytokines, modulate CD40-mediated expression of inflammatory mediators in airway epithelia: implications for the role of epithelial CD40 in airway inflammation. J Immunol 2000; 165: 2214-21.
119. Mitsuta K, Matsuse H, Fukushima C, Kawano T, Tomari S, Obase Y, et al. Production of TNF-alpha by peripheral blood mononuclear cells through activation of nuclear factor kappa B by specific allergen stimulation in patients with atopic asthma. Allergy Asthma Proc 2003; 24: 19-26.
120. Chen CL, Lee CT, Liu YC, Wang JY, Lei HY, Yu CK. House dust mite Dermatophagoides farinae augments proinflammatory mediator productions and accessory function of alveolar macrophages: implications for allergic sensitization and inflammation. J Immunol 2003; 170: 528-36.
121. Openshaw PJ, Dean GS, Culley FJ. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr Infect Dis J 2003; 22: S58-S64.
122. Caramori G, Papi A. Oxidants and asthma. Thorax 2004; 59: 170-3.
123. Salvi S. Ambient particulate air pollution and childhood asthma exacerbations. Ann Allergy Asthma Immunol 2003; 91: 321-3.
124. Bureau F, Delhalle S, Bonizzi G, Fievez L, Dogne S, Kirschvink N, et al. Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma. J Immunol 2000; 165: 5822-30.
125. Poynter ME, Irvin CG, Janssen-Heininger YM. Rapid activation of nuclear factor-kappaB in airway epithelium in a murine model of allergic airway inflammation. Am J Pathol 2002; 160: 1325-34.
126. Hart LA, Krishnan VL, Adcock IM, Barnes PJ, Chung KF. Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med 1998; 158: 1585-92.
127. Yang L, Cohn L, Zhang DH, Homer R, Ray A, Ray P. Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation. J Exp Med 1998; 188: 1739-50.
128. Das J, Chen CH, Yang L, Cohn L, Ray P, Ray A. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2001; 2: 45-50.
129. Donovan CE, Mark DA, He HZ, Liou HC, Kobzik L, Wang Y, et al. NF-kappa B/ Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation. J Immunol 1999; 163: 6827-33.
130. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003; 139: 359-70.
131. Surabhi RM, Gaynor RB. RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol 2002; 76: 12963-73.
132. Hosoya T, Takeuchi H, Kanesaka Y, Yamakawa H, Miyano-Kurosaki N, Takai K, et al. Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Lett 1999; 461: 136-40.
133. Lebruska LL, Maher LJ, III. Selection and characterization of an RNA decoy for transcription factor NF-kappa B. Biochemistry 1999; 38: 3168-74.
134. Obika S, Uneda T, Sugimoto T, Nanbu D, Minami T, Doi T, et al. 2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties. Bioorg Med Chem 2001; 9: 1001-11.
135. Nakamura H, Aoki M, Tamai K, Oishi M, Ogihara T, Kaneda Y, et al. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 2002; 9: 1221-9.
136. Griesenbach U, Scheid P, Hillery E, de Martin R, Huang L, Geddes DM, et al. Anti-inflammatory gene therapy directed at the airway epithelium. Gene Ther 2000; 7: 306-13.
137. Surabhi RM, Gaynor RB. RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol 2002; 76: 12963-73.
138. Hosoya T, Takeuchi H, Kanesaka Y, Yamakawa H, Miyano-Kurosaki N, Takai K, et al. Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Lett 1999; 461: 136-40.
139. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-9.
140. Caramori G, Adcock I. Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther 2003; 16: 247-77.
141. Liou HC, Hsia CY. Distinctions between c-Rel and other NF-kappaB proteins in immunity and disease. Bioessays 2003; 25: 767-80.
142. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 2002; 109 Suppl: S67-S79.
143. Yoshida H, Nishina H, Takimoto H, Marengere LE, Wakeham AC, Bouchard D, et al. The transcription factor NF-ATc1 regulates lymphocyte proliferation and Th2 cytokine production. Immunity 1998; 8: 115-24.
144. Ranger AM, Hodge MR, Gravallese EM, Oukka M, Davidson L, Alt FW, et al. Delayed lymphoid repopulation with defects in IL-4-driven responses produced by inactivation of NF-ATc. Immunity 1998; 8: 125-34.
145. Kiani A, Viola JP, Lichtman AH, Rao A. Down-regulation of IL-4 gene transcription and control of Th2 cell differentiation by a mechanism involving NFAT1. Immunity 1997; 7: 849-60.
146. Viola JP, Kiani A, Bozza PT, Rao A. Regulation of allergic inflammation and eosinophil recruitment in mice lacking the transcription factor NFAT1: role of interleukin-4 (IL4) and IL-5. Blood 1998; 91: 2223-30.
147. Oukka M, Ho IC, de la Brousse FC, Hoey T, Grusby MJ, Glimcher LH. The transcription factor NFAT4 is involved in the generation and survival of T cells. Immunity 1998; 9: 225-304.
148. Peng SL, Gerth AJ, Ranger AM, Glimcher LH. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity 2001; 14: 13-20.
149. Ranger AM, Oukka M, Rengarajan J, Glimcher LH. Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development Immunity 1998; 9: 627-35.
150. Rengarajan J, Tang B, Glimcher LH. NFATc2 and NFATc3 regulate T(H)2 differentiation and modulate TCR-responsiveness of naive T(H)cells. Nat Immunol 2002; 3: 48-54.
151. Frahm JL, Muddiman DC. Nucleic Acid analysis by fourier transform ion cyclotron resonance mass spectrometry at the beginning of the twenty-first century. Curr Pharm Des 2005; 11(20): 2593-613.
152. Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des 2004; 10(29): 3639-49.
153. Wu Z, MacPhee IA, Oliveira DB. Reactive oxygen species in the initiation of IL-4 driven autoimmunity as a potential therapeutic target. Curr Pharm Des 2004; 10(8): 899-913.